News
Scholar Rock market cap hits $2.7bn after spinal muscular atrophy drug apitegromab clears a phase 3 trial, with filings now expected in Q1 2025.
Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euros, and ...
View the latest Pegasystems Inc. (PEGA) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback